Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis

Abstract

Background Currently, the data regarding the effectiveness and safety of tocilizumab as treatment for COVID-19 infection is still conflicting. This study aims to give clear evidence regarding the potential benefit and safety of tocilizumab in improving the outcome of COVID-19 patients. Methods We systematically searched the PubMed and Europe PMC database using specific keywords related to our aims until November 1st, 2020. All articles published on COVID-19 and tocilizumab were retrieved. Statistical analysis was done using Review Manager 5.4 software. Results A total of 38 studies with a total of 13 412 COVID-19 patients were included in our analysis. Our meta-analysis showed that tocilizumab treatment is associated with reduction of mortality rate from COVID-19 [OR 0.54 (95% CI 0.42–0.71), p<0.00001, I 2=79%, random-effect modelling], but did not alter the severity of COVID-19 [OR 1.05 (95% CI 0.92–1.20), p=0.47, I 2=84%, random-effect modelling] and length of hospital stay [Mean Difference 1.77 days (95% CI −0.61–4.14 days), p=0.15, I 2=97%, random-effect modelling]. Tocilizumab also does not associated with serious adverse events compared with standard of care treatment [OR 0.91 (95% CI 0.71–1.15), p=0.42, I 2=46%, random-effect modelling]. Conclusion Our study does not support the routine use of tocilizumab for COVID-19 patients. Future studies should focus more on other potential therapies for COVID-19 patients.

Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

“…The result of this review suggested the benefit of IL-6 inhibitors in reducing mortality rate based on an analysis of thirteen studies. This result is in line with several recent systematic reviews that reported a lower mortality rate in the tocilizumab group than the control group [ [38] , [39] , [40] , [41] ]. COVID-19 replication causing pyroptosis of the target cell, thus inducing synthesis of pro-inflammatory cytokine [ 28 ].…”

Inflammation characteristics and anti-inflammation treatment with tocilizumab of severe/critical COVID-19 patients: A retrospective cohort study

“…Our results showed that tocilizumab treatment was associated with a lower risk of mortality, whereas were not effective for shortening time on the length of hospital stay or the time from illness onset to outcomes. In fact, consistent with our study, a meta-analysis 28 which included 38 studies reported that tocilizumab treatment is associated with a reduction of mortality from COVID-19, although tocilizumab treatment did not alter the severity of COVID-19 and the length of hospital stay. Similarly, a systematic review and meta-analysis on critically ill COVID-19 patients 16 showed tocilizumab to be efficacious in reducing mortality; moreover, another systemic review and meta-analysis also confirmed the effectiveness of tocilizumab treatment in reducing the risk of admission to ICU, use of ventilation and mortality 29 .…”

A systematic review and meta-analysis on correlation of weather with COVID-19

“…Based on our meta-analysis we found correlation between weather on the COVID-19. Temperature and humidity are most crucial weather factors that are string enough to impact over the death rate and incidence of COVID-19 42 , 43 . All the articles included into this study adhere to the weather centric approaches to the COVID-19.…”